December 1 2020

The use of immune checkpoint inhibitors across tumor types in the Veterans Affairs health care system revealed lower real-world survival outcomes than those reported in pivotal clinical trials.

The COVID-19 pandemic has brought about a currently interminable pause on in-person professional networking.

Identification of key oncogenic drivers and the development of targeted therapies with clinical activity in patients harboring actionable mutations have revolutionized the treatment paradigm in non–small cell lung cancer, redirecting attention toward advances in biomarker testing methodologies.

The emergence of tyrosine kinase inhibitors in early-stage disease is a late practice-changing development, said Roger C. Lilenbaum, MD.

After decades of use in clinical settings, targeted therapies now enjoy favored status in the cancer treatment landscape.

The MET inhibitor TPX-0022 was safe and well tolerated in a phase 1 dose-escalation study, SHIELD-1, involving patients with advanced solid tumors harboring MET alterations, according to results presented during the 32nd Molecular Targets and Cancer Therapeutics Symposium.